Episode
FCPM Sells Dyne But Watch the Milestones
- Published
- May 30, 2026
- Duration seconds
- 130
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/fcpm-sells-dyne-but-watch-the-milestones/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/fcpm-sells-dyne-but-watch-the-milestones.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
FCPM III Services B.V. just sold nearly 818,000 shares of Dyne Therapeutics for $14.1M — a major move that slashed their stake value by $22M — yet Dyne still anchors 11.8% of their portfolio. With Dyne’s stock up 60% in a year and a major FDA BLA for z-rostudirsen on deck for potential Q1 2027 launch, the company’s momentum is undeniable. They’re also launching a pivotal 72-week Phase III trial (FORZETTO) to confirm efficacy across mobility, lung function, and quality of life — all while advancing other therapies for rare muscular dystrophies. Investors are now watching closely: can Dyne turn regulatory wins into real-world commercial success? Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/c8d1dbdc855b99d5